Published:
Wednesday, July 21, 2010 1:28 PM PDT
PositiveID Corporation (Nasdaq:PSID) has completed the design of its prototype handheld Easy Check Breath Glucose Detection Device and the company said that it plans to complete the development of the prototype in the next few months. Back in May, sources told BioMedReports that a bigger company had taken an interest in partnering with PSID for a piece of the huge diabetic market that the testing unit would open up. That news sent stock prices soaring, but the news was delayed. Today, sources tell us that PSID...
Published:
Wednesday, July 21, 2010 8:19 AM PDT
The race to find a cure to Alzheimer's is heating up. This past weekend, the New York Times ran a multi-page special report on a new type of drug study that will, in the boldest effort yet, test the leading hypothesis about how to slow or stop the terrifying brain disease. A micro-cap company trading for mere pennies, Intellect Neurosciences, Inc. (ILNS.OB), has been getting increased attention because it's founder and Chairman and Chief Executive Officer, Dr. Daniel Chain, is the inventor and patent holder...
Published:
Monday, July 19, 2010 7:38 AM PDT
As we told subscribers on Friday, multiple sources have confirmed to us that a buyout of Pensylvania based BMP Sunstone Corp. (NASDAQ:BJGP) will likely take place within a matter of days. The Nasdaq listed which offers an end-to-end solution to U.S and western pharmaceutical companies wishing to sell their pharmaceutical products in China helps companies register pharmaceuticals for sale into this large and growing market. The company makes an attractive takeover target because they are priced reasonaby and...
Published:
Thursday, July 15, 2010 3:23 AM PDT
As a follow up to our interview with Northwest Biotherapeutics’ (NWBO.OB) Chairman of the Board of Linda Powers, this article focuses on the “hard differentiators” between NWBO’s immunotherapy vaccine platform and that of their closest competitor Dendreon Corporation (Nasdaq: DNDN). Observers and investors of Northwest Biotherapeutics now believe the company’s DCVax® may be poised to surpass Dendreon’s product in the field of vaccine based cancer treatments. Speculators have begun to rush back to...
Published:
Tuesday, July 13, 2010 11:52 AM PDT
In the pharmaceutical industry, a "blockbuster drug" is one that achieves acceptance by prescribing physicians as a therapeutic standard for a prevalent condition or disease.Those drugs that bring in billions of dollars, such as Lipitor, which is marketed by Pfizer for high cholesterol, Nexium by AstraZeneca for hyperacidity, and Zoloft (also marketed by Pfizer) for depression, have turned Big Pharma into one of the globe's most profitable industries. It goes without saying that drug makers spend hundreds of...
Published:
Monday, July 12, 2010 8:06 AM PDT
On Friday morning, we let our subscribers know via e-mail about a micro-cap stock that is going to be attracting a lot of attention in the weeks and months ahead.As I reported via e-mail directly to our subscribers, we have uncovered a company with several- previously undisclosed- licensing deals which many, including some of the companies themselves, may not want investors to know about just yet. Several staffers and I have done much digging since first finding out about Intellect Neurosciences, Inc. (OTC...
Published:
Tuesday, July 6, 2010 7:11 PM PDT
NeoStem, Inc. (NYSE Amex: NBS) has been selected as the "Best Stem Cell Company, 2010" in The New Economy's Biotech Awards, which identify excellence in the field of technology. The respected U.K. based and editorially independent magazine introduces its readers to exceptional thinking and progress in the fields of energy, finance, international affairs, science and technology. Sign-up for Free to Receive Future Commentary and Trading Alerts on NeoStem, Inc. (NYSE Amex: NBS). According to The New Economy's editor...
Published:
Tuesday, June 29, 2010 8:55 AM PDT
If you don't follow the company closely, you may not realize the significance of today's news announcement from NeoStem (AMEX:NBS), but the details are definitely worth noting. NBS announced today that its Suzhou Erye pharmaceutical subsidiary in China passed government inspection by that country's State Food and Drug Administration and they will now be allowed to manufacture penicillin and cephalosporin powder for injection at the company's new manufacturing facility. These two products were responsible for...
Published:
Tuesday, June 29, 2010 6:15 AM PDT
It looks like the whispers we heard on Wall Street about Hythiam, Inc. (OTCBB:HYTM) turned out to be true and they could have a significant impact on the company going forward. This morning, Hythiam is announcing that the Company has officially entered into a multi-year agreement with Health Plan of Nevada, Inc., a UnitedHealthcare® company and a leading health insurer in Nevada, to provide their Catasys® integrated substance dependence solution to its enrolled members. As we reported about the company...
Published:
Thursday, June 24, 2010 9:50 AM PDT
As a follow up to our subscriber alert and article about Access Pharmaceuticals' (ACCP.OB) presentation at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C, BioMedReports reached out to the company for reaction and specifics regarding the commercialization of the company's FDA approved product, MuGuard. Sign-up for Free to Receive Future Commentary and Trading Alerts on Access Pharmaceuticals' (ACCP.OB). The product has huge fnancial and medical potential and it...
